title: Selective splenocaval shunt for bleeding portal hypertension: fifteen-year evaluation period.
abstract: BACKGROUND
  Splenocaval shunts have been used in this hospital since 1974 as an alternative to the distal splenorenal shunt. This report will detail the long-term results with this operation.
  
  
  METHODS
  Thirty-three patients who were subjected to selective splenocaval shunts for treatment of hemorrhagic portal hypertension are reported. Mean age was 48.4 years. Twenty patients were women. Twenty-seven patients were in Child class A and six were in Child class B.
  
  
  RESULTS
  There were five postoperative deaths. Two patients experienced rebleeding. One patient had shunt obstruction and one patient had severe clinical encephalopathy. Actuarial survival rate was 54.9% at 5 years and was 47.5% at 15 years. At the time of evaluation 12 patients were alive and well (shortest observation period, 2 months and longest observation period, 173 months). One of these patients has mild encephalopathy.
  
  
  CONCLUSIONS
  Selective splenocaval shunts are a good alternative for treatment of hemorrhagic portal hypertension in patients with good liver function.
authors.affiliation: Portal Hypertension Clinic, Instituto Nacional de la Nutricion Salvador Zubiran, Mexico, D.F.
authors.forename: H
authors.initials: H
authors.lastname: Orozco
authors.forename: M A
authors.initials: MA
authors.lastname: Mercado
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: F
authors.initials: F
authors.lastname: Capellan
authors.forename: G
authors.initials: G
authors.lastname: Rojas
authors.forename: C
authors.initials: C
authors.lastname: Chan
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000601:surgery*; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011167:Portacaval Shunt, Surgical / Q000009:adverse effects / Q000379:methods*; D013162:Splenic Vein / Q000601:surgery*; D016019:Survival Analysis